Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.36 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.36 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.36 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL949316 | 1.00 | HDAC1 (0.36) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL132540 | 0.98 | HDAC1 (0.37) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL28580994 | 0.87 | HDAC3 (0.33) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| Hydrochloric Acid SCHEMBL1093848 | 0.86 | CYP1A2 (0.52) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL15653871 | 0.86 | PAOX (0.47) | HDAC1HDAC2HDAC6HDAC8LMNA | |
| Hydrochloric Acid SCHEMBL3641313 | 0.85 | BLM (0.46) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL648724 | 0.84 | CYP1A2 (0.54) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| Hydrochloric Acid SCHEMBL23045095 | 0.83 | PAOX (0.48) | HDAC1HDAC2HDAC6HDAC8LMNA | |
| SCHEMBL179682 | 0.83 | CYP1A2 (0.39) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL22832200 | 0.82 | CYP1A2 (0.52) | HDAC1HDAC2HDAC6HDAC3HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 710 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113198117-B | Combination of chlorin derivatives and ultrasound medical systems | 于波 | 2023-12-22 | — | — | CN | claimed |
| CN-116730917-A | Fluorescent probe based on naphthalimide and used for detecting nerve agent simulant | 安徽工业大学 | 2023-09-12 | — | — | CN | claimed |
| CN-111943954-B | Dihydroporphin derivative and corresponding preparation method and application thereof | 广州易斯生物科技发展有限公司 | 2021-08-13 | — | — | CN | claimed |
| CN-113198117-A | Combination of chlorin derivatives with ultrasound medical systems | 于波 | 2021-08-03 | — | — | CN | claimed |
| CN-111943954-A | Dihydroporphin derivative and corresponding preparation method and application thereof | 广州易斯生物科技发展有限公司 | 2020-11-17 | — | — | CN | claimed |
| CN-108484661-A | One kind six vanadic acid-Beta-alanine tert-butyl ester derivative and the preparation method and application thereof | 湖北工业大学 | 2018-09-04 | — | — | CN | claimed |
| CN-105367435-A | Preparation method for beta-alanine t-butyl ester hydrochloride | ZHANG WEI | 2016-03-02 | — | — | CN | claimed |
| CN-100340543-C | Cyfluthrin hapten compound, its synthesis method and use | UNIV ZHEJIANG (CN) | 2007-10-03 | — | — | CN | claimed |
| CN-1789238-A | Cyfluthrin hapten compound, its synthesis method and use | UNIV ZHEJIANG (CN) | 2006-06-21 | — | — | CN | claimed |
| CN-122075737-A | Conjugates comprising cleavable linkers | — | 2026-05-26 | — | — | CN | disclosed |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-4601705-B1 | CONJUGATES COMPRISING CLEAVABLE LINKERS | ASTRAZENECA AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4725560-A2 | ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2026-04-15 | — | — | EP | disclosed |
| US-5773612-A | VASOPRESSIN OR OXYTOCIN RECEPTORS | SANOFI (FR) | 1998-06-30 | — | — | US | disclosed |
| EP-0842175-A1 | IMIDAZOPYRIDINE DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-05-20 | — | — | EP | disclosed |
| US-5672712-A | ANTIAGGLOMERANTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1997-09-30 | — | — | US | disclosed |
| EP-0765875-A1 | THIAZOLINE DERIVATIVE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1997-04-02 | — | — | EP | disclosed |
| WO-1997006167-A1 | IMIDAZOPYRIDINE DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-02-20 | — | — | WO | disclosed |
| US-5594023-A | 1,3-dihydroindol-2-one derivatives substituted in the 3-position by a nitrogen-containing group, their preparation and the pharmaceutical compositions in which they are present | SANOFI (FR) | 1997-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | HDAC1 436/4885HDAC2 1057/4885HDAC6 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.